JamesLeonKhatcheressianMD

Oncology • Richmond, VA

Physician

Join to view full profile

Dr. Khatcheressian is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Khatcheressian's full profile

Already have an account?

Office
8007 Discovery Dr
Ste A
Richmond, VA 23229
Phone+1 804-287-3000

Fax+1 804-673-2731

Education & Training

Virginia Commonwealth University Health SystemFellowship, Hematology and Medical Oncology, 2002 - 2004
Virginia Commonwealth University School of MedicineClass of 1998

Certifications & Licensure

VA State Medical License 1998 - 2026
American Board of Internal Medicine Medical Oncology

Clinical Trials

Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies Start of enrollment: 2013 Mar 14
Terminated
Phase 2

Publications & Presentations

PubMed

20 citations
Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer
Linda T. Vahdat, Rachel M. Layman, Denise A. Yardley, William J. Gradishar, Mohamad Adham Salkeni
The Oncologist. 2017-03-01
219 citations
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.
Andrew L. Himelstein, Jared C. Foster, James L. Khatcheressian, John D. Roberts, Drew K. Seisler
JAMA. 2017-01-03
389 citations
Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
Hope S. Rugo, R. Bryan Rumble, Erin Macrae, Debra L. Barton, Hannah Klein Connolly
Journal of Clinical Oncology. 2016-09-27

Abstracts/Posters

Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma„Alone or in Combination with Rituximab
James L. Khatcheressian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Committees

Member (PGIN representative), 2015 Update Committee, American Society of Clinical Oncology (ASCO) 2015 - Present

Professional Memberships

American Society of Clinical Oncology - ASCO
Member